Bone Biologics raises $3 million in private placement

Bone Biologics Corp.

Bone Biologics Corp.

BBLG

0.00
  • Bone Biologics completed a July 2026 private placement with a single healthcare-focused institutional investor, raising about $3 million in gross proceeds.
  • Deal was priced at-the-market under Nasdaq rules.
  • Financing included Series F warrants, Series G warrants; full cash exercise could add up to about $6 million in gross proceeds.
  • Net proceeds earmarked for clinical trials, patent portfolio work, working capital, general corporate purposes.
  • Company expects the financing to extend its operating runway through Q2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bone Biologics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230800PRIMZONEFULLFEED9766626) on July 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.